Drugs in early clinical development for Systemic Lupus Erythematosus.
Drugs in early clinical development for Systemic Lupus Erythematosus.
复制标题
DOI：
10.1517/13543784.2016.1162291
复制
发表时间：
2016
影响因子：
6.1
通讯作者：
Niewold TB
中科院分区：
文献类型：
--
作者：
Postal M;Sinicato NA;Appenzeller S;Niewold TB
虽然免疫抑制治疗对系统性红斑狼疮（SLE）的预后有积极影响，但许多患者仍然对传统治疗无反应。因此，活动性SLE疾病仍然是一个重要的问题。此外，SLE的常规免疫抑制治疗与副作用的高风险相关。这些问题要求我们改进目前的治疗设备。在这篇综述中，作者重点介绍了SLE治疗的最新进展，并对处于早期临床开发阶段的SLE药物进行了概述。有许多新的治疗方法正在开发中，包括那些专注于B细胞靶点，T细胞下调，共刺激阻断，抗细胞因子剂，激酶抑制和Toll样受体抑制。他们还讨论了肽疗法作为重建免疫耐受的潜在方法，以及在开发和测试SLE新药方面面临的一些挑战。目前正在开发许多用于SLE的新药，但这一令人鼓舞的消息被临床试验中的几个失望所缓和，并提供了一个及时的时刻来反思SLE治疗发展的未来。患者之间的生物学异质性似乎是SLE药物设计困难的主要原因。
While immunosuppressive therapy has positively impacted the prognosis of systemic lupus erythematosus (SLE), many patients still do not respond to traditional therapy. Thus, active SLE disease remains a significant problem. Furthermore, conventional immunosuppressive treatments for SLE are associated a high risk of side effects. These issues call for improvement in our current therapeutic armamentarium. In this review, the authors highlight the recent developments in therapies for SLE, and present an overview of drugs which are in early clinical development for SLE. There are many new therapeutic approaches being developed, including those focused on B-cell targets, T-cell downregulation, co-stimulatory blockade, anti-cytokine agents, and kinase inhibition, and Toll-like receptor inhibition. They also discuss peptide therapy as a potential method to re-establish immune tolerance, and some of the challenges ahead in developing and testing novel agents for SLE. Many novel agents are currently in development for SLE, but this encouraging news is tempered by several disappointments in clinical trials and provides a timely moment to reflect on the future of therapeutic development in SLE. It seems likely that biological heterogeneity between patients is a major contributor to difficulty in drug design in SLE.
登录
查看更多内容
影响因子：
27.4
作者：
Bertsias GK;Tektonidou M;Amoura Z;Aringer M;Bajema I;Berden JH;Boletis J;Cervera R;Dörner T;Doria A;Ferrario F;Floege J;Houssiau FA;Ioannidis JP;Isenberg DA;Kallenberg CG;Lightstone L;Marks SD;Martini A;Moroni G;Neumann I;Praga M;Schneider M;Starra A;Tesar V;Vasconcelos C;van Vollenhoven RF;Zakharova H;Haubitz M;Gordon C;Jayne D;Boumpas DT;European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association
通讯作者：
European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association
影响因子：
2.6
作者：
Aringer, M.;Burkhardt, H.;Doerner, T.
通讯作者：
Doerner, T.
影响因子：
158.5
作者：
Arbuckle, MR;McClain, MT;Harley, JB
通讯作者：
Harley, JB
影响因子：
3.1
作者：
Amarilyo, Gil;Hahn, Bevra;La Cava, Antonio
通讯作者：
La Cava, Antonio
DOI：
10.1002/art.38790
发表时间：
2014-11
期刊：
Arthritis & rheumatology (Hoboken, N.J.)
影响因子：
--
作者：
ACCESS Trial Group
通讯作者：
ACCESS Trial Group